StoryTest
BioAge reports full BGE-102 Phase 1 data with about 85% median hsCRP reduction and no serious adverse events
BioAge's complete Phase 1 data for BGE-102 showed median hsCRP reductions of 80–86%, with 93% of participants achieving normal hsCRP levels (<2 mg/L). There were no serious adverse events, clearing the path for Phase 2 cardiovascular and ophthalmology trials.
- 120 mg and 60 mg doses achieved ≥85% median hsCRP reduction; 93% reached levels <2 mg/L (cardiovascular risk threshold).
- Consistent reductions across multiple inflammatory biomarkers; well tolerated with no dose-limiting toxicities.
- Phase 2 cardiovascular trial planned for mid-2026 with results by year-end; Phase 1b/2a diabetic macular edema trial also planned.